Inmagene Biopharmaceutical ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") announce that the first participant, based in the United States, was dosed in a global Phase...
Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced...
